TILT Biotherapeutics Ltd.
Haartmaninkatu 3, 4th Floor
About TILT Biotherapeutics Ltd.TILT Biotherapeutics Ltd is a preclinical stage company working in the field of cancer immunotherapy. TILT aims to translate its unique approach into clinical trials. The company’s patented technology involves utilization of oncolytic viruses for enhancement of tumor T-cell therapy. Initial embodiments of the technology will be used to enhance tumor infiltrating lymphocyte (TIL), chimeric antigen receptor (CAR) and checkpoint inhibiting antibody therapy. The TILT approach has the potential to achieve similar results in CAR therapy of solid tumors as currently achieved for CD19+ hematological tumors.
Founder and CEO: Akseli Hemminki
10 articles with TILT Biotherapeutics Ltd.
TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapeutics, announces that it has submitted an IND for its Phase I trial of immunotherapeutic TILT-123 in ovarian cancer.
TILT Biotherapeutics, Docrates Cancer Center and Helsinki University Hospital Open Cancer Immunotherapy Clinical Trial
TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapeutics, announces that it has dosed its first patients and progressed to the second dose level in a monotherapy phase 1 clinical trial of TILT-123, a dual cytokine armed oncolytic adenovirus.
TILT Biotherapeutics and MSD to Collaborate on Clinical Trial of Adenoviral Cancer Immunotherapeutic TILT-123 in Combination with KEYTRUDA® (pembrolizumab) for Ovarian Cancer
TILT Biotherapeutics announced a clinical trial collaboration agreement with MSD, a premier research-intensive biopharmaceutical company, to evaluate TILT’s adenoviral cancer immunotherapy TILT-123, a dual cytokine armed oncolytic adenovirus, in combination with KEYTRUDA®, MSD’s anti-PD-1 therapy, in a Phase I dose escalation trial in platinum resistant or refractory ovarian cancer.
TILT Biotherapeutics Announces Two Patients Pass Primary Safety Endpoint in European Cancer Immunotherapy Trial
TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapeutics, announces it has dosed two patients in a phase 1 clinical trial of its dual cytokine armed oncolytic adenovirus, TILT-123, in Denmark’s Herlev hospital in Copenhagen.
EUR 18m raised to date, with investors including Lifeline Ventures, Finnish private investors, the European Innovation Council and Business Finland
TILT Biotherapeutics Signs a Licensing Deal with Biotheus, Inc for Cancer Therapy with Oncolytic Virus TILT-123
TILT Biotherapeutics (“TILT”), a privately held biopharmaceutical company based in Helsinki, Finland, today announces that they have signed a license agreement with Biotheus Inc. (“Biotheus”), a privately held Chinese company based in Zhuhai, Guangdong, China.
Engagement highlights TILT’s renewed focus on corporate communication
TILT Biotherapeutics Initiates Collaboration With Merck KGaA, Darmstadt, Germany and Pfizer Investigating the Combination of Oncolytic Virus, TILT-123, And Anti-PDL1 Antibody, Avelumab
Agreement to evaluate its armed oncolytic virus, TILT-123, with avelumab in patients with solid tumors refractory to routine modalities.
TILT Biotherapeutics Ltd has won a grant for a 2.5 M€ (~$ 2.9M) project, entitled UNLEASHAD, from the European Commission EIC SME Instrument.